Germany’s Merck KGaA to buy Serono

Germany’s Merck KGaA is buying a majority stake in Swiss rival Serono in a deal worth approximately $13.3 billion, according to published reports. Merck said it is buying a 64.5% stake in Serono that will give it 75.5% of voting rights, The Wall Street Journal reported. “Details of the financing will be provided prior to closing, early 2007,” a Merck spokesman said. Merck produces chemicals such as liquid crystals and drugs including cancer treatment Erbitux. Merck’s pipeline virtually dried up in June when its Parkinson’s disease drug Sarizotan failed in late-stage clinical tests. Serono’s sales increased 2.8% in the second quarter, with the company’s main product, multiple sclerosis treatment Rebif, contributing to the rise.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.